{"id":"drug-budesonide-formoterol-symbicort-turbuhaler","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Palpitations"},{"rate":"1-5%","effect":"Oral candidiasis"},{"rate":"1-5%","effect":"Nervousness/anxiety"},{"rate":"1-5%","effect":"Muscle cramps"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:17:59.631774","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Budesonide/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:47.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"_fixedFields":["pubmed(50)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"recentPublications":[{"date":"2025 Sep","pmid":"40310281","title":"Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically-Based Pharmacokinetic Model.","journal":"Clinical pharmacology and therapeutics"},{"date":"2025 Jul","pmid":"40118212","title":"Long-Term Effectiveness of a Digital Inhaler on Medication Adherence and Clinical Outcomes in Adult Asthma Patients in Primary Care: The Cluster Randomized Controlled ACCEPTANCE Trial.","journal":"The journal of allergy and clinical immunology. In practice"},{"date":"2022 Aug 12","pmid":"36286942","title":"[Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation].","journal":"Terapevticheskii arkhiv"},{"date":"2022","pmid":"35173123","title":"[CHARACTERISTICS OF BUDEFORU(®) FOR BUDESONIDE AND FORMOTEROL MIXTURE].","journal":"Arerugi = [Allergy]"},{"date":"2021 Oct 31","pmid":"34612663","title":"Adjunctive Probiotics Alleviates Asthmatic Symptoms via Modulating the Gut Microbiome and Serum Metabolome.","journal":"Microbiology spectrum"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Drug: Budesonide/formoterol (Symbicort Turbuhaler","genericName":"Drug: Budesonide/formoterol (Symbicort Turbuhaler","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}